Locations
Company type
Result types
Industries
Employees
Founding year
The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Result configuration
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
PEPTIDE INSTITUTE
Japan
A
- Employees
-
Key takeaway
The company specializes in peptide synthesis and purification, leveraging advanced techniques to produce high-quality research peptides and bioactive peptides.
Reference
Product
ペプチド合成 | 株式会社ペプチド研究所
当社は、前身の蛋白質研究奨励会より受け継がれたペプチド合成と精製、および分析技術を駆使して高品質の研究用ペプチド合成試薬や生理活性ペプチド、およびそのペプチド抗体の製造、販売を行って参りました。また現在では医薬品原薬製造...
GeneFrontier Japan
Sakai, Japan
A
- Employees
2010
Key takeaway
The company specializes in protein engineering and biologics, focusing on innovative therapeutic solutions, including a platform for cyclic peptides and high-functionality antibodies.
Reference
Product
Drug Discovery | 日本語版
PRISM BioLab
Fujisawa, Japan
A
11-50 Employees
2006
Key takeaway
PRISM BioLab specializes in peptide therapeutics, utilizing their PepMetics Technology to develop peptide mimetic small molecules that can transform "undruggable" targets into viable drug candidates. Their innovative approach focuses on modulating protein-protein interactions, which is crucial in drug discovery and development.
Reference
Product
Peptide Mimetics - PRISM BioLab
PRISM’s unique mimetic technology develops and synthesizes compounds designed to mimic α-helix and β-turn peptides found within the secondary structure of proteins. This technology enables PRISM to modulate intracellular and ectodomain protein-protein interactions (PPIs). PRISM’s proprietary scaffolds allow the precise structural mimicking of peptide scaffolds as well as the flexible arrangement of natural or modified […]
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
Red Arrow Therapeutics
Tokyo, Japan
A
1-10 Employees
2021
Key takeaway
Red Arrow Therapeutic is a biotech startup focused on developing innovative drug delivery systems using nanotechnology.
Reference
Core business
HOME | Red Arrow Theraputic
Libero Thera
Osaka, Japan
A
1-10 Employees
2018
Key takeaway
LiberoThera Co., Ltd. is focused on innovative drug development that contributes to healthcare, utilizing cell-free membrane protein preparation technology and non-natural amino acid incorporation techniques. Their research particularly targets antibody therapeutics for GPCRs.
Reference
Core business
リベロセラ株式会社 - 無細胞膜タンパク質調製技術 および 非天然型アミノ酸導入技術 を用いた革新的な創薬を通じ医療に貢献します。
無細胞膜タンパク質調製技術 および 非天然型アミノ酸導入技術 を用いた革新的な創薬を通じ医療に貢献します。 - GPCRを標的とした抗体医薬を中心に創薬を行っています。
Molcure
Tokyo, Japan
A
11-50 Employees
2013
Key takeaway
The company utilizes proprietary methods and AI technology to identify valuable peptides and antibodies by predicting their fundamental properties, which is crucial for peptide therapeutics. Through directed evolution experiments and advanced machine learning models, they enhance the drug discovery process.
Reference
Core business
Molcure Inc. | Accelerating drug discovery
AceRNA
Kyoto, Japan
A
1-10 Employees
2018
Key takeaway
The company is a biotech startup dedicated to creating innovative genetic therapies that specifically target disease-causing cells, aiming to minimize patient burden. They are focused on developing new treatments in collaboration with partner companies, utilizing advanced technologies like RNA Switches.
Reference
Core business
News - aceRNA
aceRNA
T Cell Nouveau
Tokyo, Japan
A
1-10 Employees
2021
Key takeaway
The company, T Cell Nouveau Inc., is advancing peptide therapeutics through its patented TCR-like CAR T-cell therapy, which targets solid tumors that are resistant to conventional CAR and TCR therapies. Their unique technology includes a TCR-like CAR antibody that shows high specificity for peptide-HMC complexes, enhancing the activation and persistence of T cell functions in immunosuppressive tumor microenvironments.
Reference
Core business
Car-t細胞療法 | T Cell Nouveau、ティーセルヌーヴォー株式会社 | 東京都
ティーセルヌーヴォー株式会社は臨床段階のバイオメディカル企業であり、三重大学 珠玖研究室が開発した最先端のTCR like CAR-T細胞療法を用いて、免疫系を賦活化することにより固形がんを治療することを目指しています。私たちのユニークなTCR like CAR T細胞療法は、近年のCAR-T細胞療法あるいはTCR-T細胞療法が奏功しない固形がんの治療を目指す飛躍的な革新技術であると強く信じています。私たちの特許技術であるTCR like CAR抗体は、ペプチド-HMC複合体における標的抗原（MAGE4またはPRAME）に対して高い特異性を有しています。さらに、私たちの特許技術であるシグナルドメイン構造は、免疫抑制性のがん微小環境において、T cell機能の活性化、維持及び持続を助けます。
mAbProtein
Izumo, Japan
A
1-10 Employees
2018
Key takeaway
mAbProtein is focused on driving innovation in antibody development, which may relate to advancements in peptide therapeutics.
Reference
Core business
マブプロテイン｜抗体製造 mAbProtein | 島根大学発のバイオベンチャー
WATANABE CHEMICAL INDUSTRIES
Hiroshima, Japan
A
51-100 Employees
1952
Key takeaway
The company offers a wide range of over 2,500 products, including reagents for peptide synthesis and amino acid derivatives.
Reference
Core business
アミノ酸・アミノ酸誘導体・ペプチド合成用試薬 渡辺化学工業株式会社
Technologies which have been searched by others and may be interesting for you:
When exploring the Peptide Therapeutics industry in Japan, several key considerations emerge. Japan is known for its advanced healthcare system and strong emphasis on research and development, making it a significant player in the global peptide market. Regulatory frameworks are stringent, governed by the Pharmaceuticals and Medical Devices Agency (PMDA), which ensures that all therapeutic peptides comply with safety and efficacy standards. This can pose challenges for new entrants due to the lengthy approval processes. The competitive landscape is marked by both domestic companies and international firms, fostering innovation but also creating a crowded market. Opportunities exist in the aging population's demand for targeted therapies, particularly in oncology and metabolic disorders. Environmental concerns, such as the sustainability of raw materials used in peptide synthesis, are increasingly relevant as companies aim to align with global sustainability goals. Furthermore, collaborations and partnerships with research institutions and universities can enhance innovation and expedite product development. Understanding these dynamics is crucial for anyone considering engagement in the peptide therapeutics sector in Japan, as they will provide insights into potential risks and avenues for growth.
Some interesting numbers and facts about your company results for Peptide Therapeutics
| Country with most fitting companies | Japan |
| Amount of fitting manufacturers | 31 |
| Amount of suitable service providers | 10 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 1952 |
| Youngest suiting company | 2021 |
Some interesting questions that has been asked about the results you have just received for Peptide Therapeutics
What are related technologies to Peptide Therapeutics?
Based on our calculations related technologies to Peptide Therapeutics are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Who are Start-Ups in the field of Peptide Therapeutics?
Start-Ups who are working in Peptide Therapeutics are Red Arrow Therapeutics, T Cell Nouveau
Which industries are mostly working on Peptide Therapeutics?
The most represented industries which are working in Peptide Therapeutics are Other, Biotechnology, Chemicals, IT, Software and Services, Pharmaceuticals
How does ensun find these Peptide Therapeutics Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.